Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007547 | 1.00 | GRM2 (0.69) | GRM2F10 | |
| SCHEMBL9550277 | 0.91 | F10 (0.60) | GRM2F10 | |
| SCHEMBL9844322 | 0.87 | GRM2 (0.69) | GRM2 | |
| SCHEMBL14168239 | 0.87 | F10 (0.66) | GRM2F10 | |
| SCHEMBL12728922 | 0.84 | GRM2 (0.64) | GRM2F10 | |
| SCHEMBL28767300 | 0.84 | F10 (0.63) | GRM2F10 | |
| SCHEMBL3328770 | 0.84 | F10 (0.63) | GRM2F10 | |
| SCHEMBL21297020 | 0.84 | F10 (0.59) | GRM2F10 | |
| SCHEMBL9823520 | 0.84 | F10 (0.63) | GRM2F10 | |
| SCHEMBL15203256 | 0.84 | GRM2 (0.64) | GRM2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2722330-B1 | NOVEL METHOD FOR SYNTHESIZING RIVAROXABAN INTERMEDIATE, 4-{4-[(5S)-5-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL}MORPHOLIN-3-ONE | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2017-04-26 | — | — | EP | claimed |
| EP-2722330-A1 | NOVEL METHOD FOR SYNTHESIZING RIVAROXABAN INTERMEDIATE, 4-{4-[(5S)-5-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIGDIN-3-YL]PHENYL}MORPHOLIN-3-ONE | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2014-04-23 | — | — | EP | claimed |
| EP-0434714-A1 | IN POSITION 3 SUBSTITUTED-5-BETA-AMIDOMETHYL-OXAZOLIDIN-2-ONES | THE UPJOHN COMPANY (US) | 1991-07-03 | — | — | EP | claimed |
| WO-1990002744-A1 | IN POSITION 3 SUBSTITUTED-5-BETA-AMIDOMETHYL-OXAZOLIDIN-2-ONES | THE UPJOHN COMPANY (US) | 1990-03-22 | — | — | WO | claimed |
| US-9376427-B2 | Process for preparing rivaroxaban using intermediates | SYMED LABS LIMITED (IN) | 2016-06-28 | — | — | US | disclosed |
| US-20150126733-A1 | IMPROVED PROCESS FOR PREPARING RIVAROXABAN USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2015-05-07 | — | — | US | disclosed |
| WO-2014155259-A2 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | GLENMARK PHARMACEUTICALS LIMITED; GLENMARK GENERICS LIMITED (IN) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013027225-A1 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2013-02-28 | — | — | WO | disclosed |
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-25 | — | — | US | disclosed |
| WO-2008143649-A2 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-11-27 | — | — | WO | disclosed |
| US-20080214565-A1 | Oxazolidinone Derivatives as Antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2008-09-04 | — | — | US | disclosed |
| US-20060293307-A1 | Oxazolidinone derivatives as antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2006-12-28 | — | — | US | disclosed |
| WO-2004069816-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-19 | — | — | WO | disclosed |
| US-6734307-B2 | USE AGAINST MULTIPLY RESISTANT GRAM POSITIVE PATHOGENS; HAVE A DIAZINE MOIETY ATTACHED TO THE PHENYLOXAZOLIDINONE WHICH IS FURTHER SUBSTITUTED BY HETEROCYCLIC, ARYL, SUBSTITUTED ARYL, HETEROAROAMATIC RING | RANBAXY LABORATORIES LIMITED (IN) | 2004-05-11 | — | — | US | disclosed |
| WO-2004014392-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2004-02-19 | — | — | WO | disclosed |
| US-20030119817-A1 | Oxazolidinone derivatives as potential antimicrobials | MEHTA ANITA (IN) | 2003-06-26 | — | — | US | disclosed |
| EP-1303511-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2003-04-23 | — | — | EP | disclosed |
| US-20020103186-A1 | Oxazolidinone derivatives as antimicrobials disease | RANBAXY LABORATORIES LIMITED (IN) | 2002-08-01 | — | — | US | disclosed |
| WO-2002006278-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2002-01-24 | — | — | WO | disclosed |
| US-6069160-A | Heteroatom-containing benzocyclopentane-oxazolidinones | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119817-A1 | Oxazolidinone derivatives as potential antimicrobials | OXA1L, PDK4, SDHA | GRM2 3938/4885F10 1559/4885 |
| US-20150126733-A1 | IMPROVED PROCESS FOR PREPARING RIVAROXABAN USING NOVEL INTERMEDIATES | SULT1E1, CYP2C9, VKORC1 | GRM2 1685/4885F10 194/4885 |
| US-20020103186-A1 | Oxazolidinone derivatives as antimicrobials disease | OXA1L, MLYCD, TBCD | GRM2 4151/4885F10 836/4885 |
| US-20060293307-A1 | Oxazolidinone derivatives as antimicrobials | OXA1L, PDK4, SDHA | GRM2 3672/4885F10 1403/4885 |
| US-20080214565-A1 | Oxazolidinone Derivatives as Antimicrobials | OXA1L, SDHA, PDK4 | GRM2 4111/4885F10 1210/4885 |
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | OXA1L, MIF, VIP | GRM2 2504/4885F10 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.